Last update 26 Jun 2025
Zhejiang Crownmab Biotech Co. Ltd.

Zhejiang Crownmab Biotech Co. Ltd.

Subsidiary Company|2018|Zhejiang Sheng, China|
www.apollomicsinc.com

Overview

Tags

Neoplasms
Hemic and Lymphatic Diseases
Other Diseases
Monoclonal antibody
Biological products
Small molecule drug

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Neoplasms5
Hemic and Lymphatic Diseases2
Immune System Diseases2
Nervous System Diseases1
Top 5 Drug TypeCount
Monoclonal antibody2
Biological products1
Small molecule drug1
Bispecific antibody1
Top 5 TargetCount
PD-1(Programmed cell death protein 1)1
E-sel(Selectin E)1
CTLA4(Cytotoxic T-Lymphocyte-Associated Antigen 4)1
CD40 x PDL11

Related

5
Drugs associated with Zhejiang Crownmab Biotech Co. Ltd.
Genolimzumab
Target
PD-1
Mechanism
PD-1 inhibitors
Active Org.
Genor Biopharma Co., Ltd.Genor Biopharma Co., Ltd. [+1]
Originator Org.
Zhejiang Crownmab Biotech Co. Ltd.Zhejiang Crownmab Biotech Co. Ltd.
Active Indication
Uterine Cervical Cancer [+16]
Inactive Indication
Advanced Malignant Solid Neoplasm [+12]
Drug Highest PhasePhase 3
First Approval Ctry. / Loc.-
First Approval Date-
APL-108
Target
E-sel
Mechanism
E-sel inhibitors
Active Org.
Zhejiang Crownmab Biotech Co. Ltd.Zhejiang Crownmab Biotech Co. Ltd.
Originator Org.
Apollomics, Inc. (United States)Apollomics, Inc. (United States)
Active Indication
Multiple Myeloma
Inactive Indication-
Drug Highest PhasePreclinical
First Approval Ctry. / Loc.-
First Approval Date-
APL-612
Target-
Mechanism
Immunomodulators
Active Org.
Zhejiang Crownmab Biotech Co. Ltd.Zhejiang Crownmab Biotech Co. Ltd.
Originator Org.-
Active Indication
Neoplasms
Inactive Indication-
Drug Highest PhasePreclinical
First Approval Ctry. / Loc.-
First Approval Date-
3
Clinical Trials associated with Zhejiang Crownmab Biotech Co. Ltd.
NCT05054543
/ Unknown statusPhase 3
A Phase 3 Randomized, Double-Blinded Bridging Trial to Evaluate the Efficacy of Uproleselan Administered With Chemotherapy Versus Chemotherapy Alone in Chinese Patients With Relapsed/Refractory Acute Myeloid Leukemia
NCT05055518
/ Unknown statusPhase 1
Phase I Study on Safety, Tolerance, and Pharmacokinetics of APL-102 Capsule in Patients With Advanced Solid Tumors
NCT04839341
/ Unknown statusPhase 1
A Phase I, Open-labeled Multicenter Study to Determine Pharmacokinetics, Safety, Tolerability and Efficacy of Uproleselan in Combination With Chemotherapy in Chinese Patients With Relapsed/Refractory Acute Myeloid Leukemia
100 Clinical Results associated with Zhejiang Crownmab Biotech Co. Ltd.
Login to view more data
0 Patents (Medical) associated with Zhejiang Crownmab Biotech Co. Ltd.
Login to view more data
100 Deals associated with Zhejiang Crownmab Biotech Co. Ltd.
Login to view more data
100 Translational Medicine associated with Zhejiang Crownmab Biotech Co. Ltd.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 05 Jul 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Discovery
1
3
Preclinical
Phase 2
1
9
Other
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
Genolimzumab
 ( PD-1 )		Sarcoma
More
Phase 2
APL-612
Neoplasms
More
Preclinical
APL-108
 ( E-sel )		Multiple Myeloma
More
Preclinical
10B-10
 ( CTLA4 )		Neoplasms
More
Preclinical
APL-801
 ( CD40 x PDL1 )		Neoplasms
More
Discovery
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free